Millions of Americans currently take cardiovascular medications to treat or prevent heart disease and many have problems finding the right drug and dose. Major pharmacogenetic strides over the past decade have led the way to leveraging genetic information to guide therapies for cardiovascular patients — especially treatments that include clopidogrel, warfarin, and statins.[13]
Other genetic pathways include CYP2C9, CYP3A4, CYP3A5, VKORC1, F2/Factor II, F5/Factor V Leiden, MTHFR and SLCO1B1. Your genes are the main factor determining the level of these enzymes in your liver. If you have too much of the enzyme, you process the medication too quickly: too little of the enzyme and the medication builds up in your bloodstream, potentially causing adverse reactions or side effects. Without knowing your genetics, your physician may need to go through months of trial-and-error prescribing to find the right drug and dose for you.
PGx AND HEART DISEASE
Discover the Right Treatment for Heart Disease, Faster
Genelex pharmacogenetic testing complements current efforts to optimize treatment of heart disease and leans towards effective and personalized care —while being more cost effective and reducing trial-and-error efforts.
With advances in genetics, you are now able to optimize your response to cardiovascular drugs and many other medications through DNA testing. In partnership with YouScript, a leader in drug-drug and drug-gene interaction software, you'll get a report highlighting patient-specific genetic markers and potential interactions, allowing for drug and dosage decisions to be catered to your needs.
Population Frequency of Cytochrome P450 (CYP) Metabolizer Types [5]
| Poor (no or low enzyme levels) |
Intermediate (reduced enzyme levels) |
normal (normal enzyme levels) |
Rapid or Ultra Rapid Metabolizer (high enzyme levels) |
|
|---|---|---|---|---|
| CYP2D6* | 4-7% | 9-35% | 50-90% | 2-3% |
| CYP2C9 | 3% | 30% | 68% | N/A |
| CYP2C19* | 2-20% | 24-36% | 14-44% | 30% |
*CYP2C19 variability depends on ethnicity.
*CYP2D6 Variability depends on ethnicity and classification of Intermediate activity
Additional heart disease medications that are impacted by your genetics:[15]
| Trade Name | Drug |
|---|---|
| Arixtra® | fondaparinux |
| Avapro® | irbesartan |
| Blocadren Timoptic® | timolol |
| Brilinta® | ticagrelor |
| Bystolic® | nebivolol |
| Cardura®, Doxadura® | doxazosin |
| Coreg® | carvedilol |
| Coumadin®, Jantoven® | warfarin |
| Cozaar® | losartan |
| Crestor® | rosuvastatin |
| Demadex® | torsemide |
| Edarbi® | azilsartan kamedoxomil |
| Effient® | prasugrel |
| Eliquis® | apixaban |
| Inderal®, InnoPran®, Hemangeol® | propranolol |
| Lescol® | fluvastatin |
| Lipitor® | atorvastatin |
| Livalo® | pitavastatin |
| Lopressor®, Toprol® | metoprolol |
| Mevacor®, Altocor®, Altoprev® | lovastatin |
| Mexitil® | mexiletine |
| Normodyne®, Trandate® | labetalol |
| Plavix® | clopidogrel |
| Pradaxa® | dabigatran-etexilate |
| Pravachol® | pravastatin |
| Ranexa® | ranolazine |
| Rythmol® | propafenone |
| Tambocor® | flecainide |
| Xarelto® | rivaroxaban |
| Zocor® | simvastatin |
| Zontivity® | vorapaxar |
Patient Resources
Take a Risk Assessment
Simply enter the medications you’re currently on or plan to take. Click “Get Results” to see if your regimen puts you at risk for an adverse drug reaction.
YOUR GENELEX RISK ASSESSMENT RESULTS: